Advances in HIV management and challenges in Japan: Current situation of pre-exposure prophylaxis in Tokyo, Japan

• Published in: Global Health & Medicine 2024/10/31, Vol.6(5), pp.304-309
• Main Authors: Mizushima, Daisuke, Gatanaga, Hiroyuki, Oka, Shinichi
• Format: Article
• Language: English
• Subjects: antiretroviral therapy; HIV; preexposure prophylaxis
• ISSN: 2434-9186; 2434-9194
• DOI: 10.35772/ghm.2024.01043

Since the world's first case series of human immunodeficiency virus (HIV) infection were reported, more than 40 decades have passed. The advancement of HIV treatment and prevention has progressed drastically. Especially, the efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention has been proven by a number of trials and the number of new HIV cases has declined over the years due to the large-scale and rapid implementation of PrEP and universal HIV treatment in multiple countries. However, in Japan, PrEP is not approved or officially supported as of June 2024. Despite of the absence of top-down movement, men who have sex with men (MSM)-friendly private clinics initiated prescriptions of generic medicines for oral PrEP with necessary tests in Tokyo, which greatly contributed to improve access to PrEP. It is of note that current situation of bottom-up PrEP implementation using generic medicines in Tokyo is obviously cost-saving, which is needless to evaluate. However, expense of PrEP is fully out-of-pocket, which will hinder those with low or no income from accessing PrEP services despite the low prices of generic medicines. Furthermore, current PrEP implementation based on user-friendly clinics is functioning only in Tokyo. The role of public health authorities is important to solve these financial and geographical disparities in accessing PrEP services, without impairing existing virtues of accessibility and cost-saving in the current system.